Table 2.

Summary of patient characteristics

Clinically determined CIO (N = 190)Geometric mean of hearing thresholds (N = 200)
Cases (N = 37)Controls (N = 153)P valueCases (N = 33)Controls (N = 167)P value
Age at time of treatment (years), median (IQR)40 (32–49)29 (23–35)3.00 × 10−740 (31–51)30 (24–35)3.11 × 10−7
Cumulative cisplatin dose (mg/m2), median (min, max)400 (300–920)400 (300–800)0.005400 (200–920)400 (200–900)0.012
Concomitant ototoxic medication,an (%)1 (2.7)4 (2.6)1.0001 (3.0)6 (3.6)1.000
Cranial irradiation, n (%)1 (2.7)2 (1.3)0.4801 (3.0)1 (0.6)0.304
Cancer treatment protocol0.0780.012
BEP, n (%)17 (45.9)102 (66.7)0.02414 (42.4)114 (68.3)0.009
EP, n (%)13 (35.1)32 (20.9)0.08511 (33.3)32 (19.2)0.038
VIP2, n (%)1 (2.7)6 (3.9)1.0001 (3.0)8 (4.8)0.357
Combination, n (%)6 (16.2)13 (8.5)0.2177 (21.2)13 (7.8)0.028
Proportion ancestry European, median IQR)0.85 (0.81–0.90)0.81 (0.70–0.87)0.0180.85 (0.81-0.91)0.81 (0.70- 0.87)0.036
East Asian, median (IQR)0.02 (0.00–0.04)0.01 (0.00- 0.05)0.6360.02 (0.00–0.04)0.01 (0.00–0.05)0.190
South Asian, median (IQR)0.08 (0.03- 0.14)0.07 (0.02–0.12)0.5640.08 (0.03–0.14)0.07 (0.02–0.12)0.253
American, median (IQR)0.01 (0.00–0.05)0.02 (0.00–0.05)0.1670.01 (0.00–0.05)0.02 (0.00–0.05)0.102
African, median (IQR)0.02 (0.00–0.03)0.03 (0.02–0.05)0.0750.02 (0.00–0.03)0.03 (0.01–0.05)0.077
  • BEP: 20 mg/m2 cisplatin, 100 mg/m2 etoposide, 30 units bleomycin for 5 days per cycle; EP: 20 mg/m2 cisplatin, 100 mg/m2 etoposide for 5 days per cycle, IQR: interquartile range; max: maximum; min: minimum; VIP2: 20 mg/m2 cisplatin, 75 mg/m2 etoposide, 1500 mg/m2 ifos, 300 mg/m2 mesna for 5 days per cycle.

  • aTobramycin, vancomycin, vincristine, furosemide. Significant P values (P < 0.05) are bolded. Proportion ancestry was calculated using ADMIXTURE, including five ancestral components.